Cytosorbents Corporation (NASDAQ:CTSO) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

A number of other brokerages also recently weighed in on CTSO. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Cytosorbents Corporation in a report on Tuesday, September 26th. B. Riley reissued a “buy” rating and set a $11.25 price target on shares of Cytosorbents Corporation in a research report on Saturday, August 12th. Maxim Group increased their price target on shares of Cytosorbents Corporation from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Aegis restated a “buy” rating and set a $9.00 price target on shares of Cytosorbents Corporation in a report on Tuesday, July 25th. Finally, Cowen and Company began coverage on shares of Cytosorbents Corporation in a research report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Cytosorbents Corporation currently has an average rating of “Buy” and an average price target of $12.71.

Cytosorbents Corporation (CTSO) traded down 0.81% during trading on Monday, reaching $6.15. The company had a trading volume of 328,661 shares. Cytosorbents Corporation has a 12 month low of $3.30 and a 12 month high of $6.90. The stock has a 50 day moving average price of $5.36 and a 200 day moving average price of $4.80. The firm’s market capitalization is $173.02 million.

Cytosorbents Corporation (NASDAQ:CTSO) last announced its earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. The company had revenue of $3.57 million for the quarter, compared to the consensus estimate of $3.29 million. Cytosorbents Corporation had a negative net margin of 80.56% and a negative return on equity of 529.95%. On average, equities research analysts predict that Cytosorbents Corporation will post ($0.27) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/02/cytosorbents-corporation-ctso-rating-lowered-to-sell-at-valuengine.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Segantii Capital Management Ltd raised its holdings in shares of Cytosorbents Corporation by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock valued at $122,000 after buying an additional 23,100 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Cytosorbents Corporation by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after purchasing an additional 22,500 shares during the last quarter. Cowen Group Inc. bought a new stake in Cytosorbents Corporation during the 1st quarter worth about $248,000. Sabby Management LLC acquired a new position in Cytosorbents Corporation during the 1st quarter valued at about $990,000. Finally, Skylands Capital LLC lifted its position in Cytosorbents Corporation by 87.7% during the 2nd quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock valued at $2,555,000 after purchasing an additional 277,650 shares during the period. 6.89% of the stock is owned by institutional investors.

About Cytosorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Stock Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related stocks with our FREE daily email newsletter.